Compare GIII & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIII | MPLT |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2006 | N/A |
| Metric | GIII | MPLT |
|---|---|---|
| Price | $34.95 | $36.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $29.00 | ★ $32.67 |
| AVG Volume (30 Days) | 513.7K | ★ 563.2K |
| Earning Date | 06-05-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $2,957,012,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.02 | $12.24 |
| 52 Week High | $36.53 | $40.43 |
| Indicator | GIII | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 54.74 |
| Support Level | $31.83 | $26.20 |
| Resistance Level | $36.43 | $40.43 |
| Average True Range (ATR) | 0.90 | 2.75 |
| MACD | -0.02 | -0.46 |
| Stochastic Oscillator | 56.62 | 35.78 |
G-III Apparel Group Ltd is an apparel manufacturing company. The company makes a wide range of apparel, footwear, and accessories that sells under its own brands, licensed brands, and private-label brands. It has a substantial portfolio for licensed and proprietary brands, anchored by brands: DKNY, Donna Karan, Karl Lagerfeld, Karl Lagerfeld Paris, Vilebrequin, and others. The reportable segments of the company are Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, and sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenue from Wholesale operations.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.